AAV Vector Delivery of ARSB for MPS VI Corneal Clouding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mucopolysaccharidosis VI (MPS VI), such as enzyme replacement therapy and hematopoietic stem cell transplantation, are ineffective in correcting ocular abnormalities and corneal clouding, leading to significant vision loss in patients due to the inability to deliver therapeutic enzymes to privileged compartments like the eye.
Innovation Solution
The use of adeno-associated virus (AAV) vectors to deliver codon-optimized arylsulfatase B (ARSB) to the cornea, enabling effective expression and reducing corneal clouding and other ocular manifestations associated with MPS VI.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy or hematopoietic stem cell transplantation is used to treat MPS VI, then systemic symptoms such as hepatosplenomegaly and joint mobility are improved, but ocular abnormalities and corneal clouding remain untreated
Solution Approach 1:
The patent employs adeno-associated virus (AAV) vectors as intermediary carriers to deliver ARSB enzyme specifically to the cornea. The AAV vector acts as a mediator that overcomes the blood-eye barrier, enabling targeted delivery of therapeutic enzyme to the privileged ocular compartment that cannot be reached by systemic ERT or HSCT alone.
Solution Approach 2:
The invention implements local quality by directing the therapeutic effect specifically to the cornea through corneal injection of AAV vectors. This localized delivery approach concentrates the ARSB enzyme expression at the site of pathology (corneal stroma) rather than relying on systemic distribution, thereby treating the privileged compartment effectively.
2Reliability
If corneal transplantation is performed to address corneal blindness in MPS VI patients, then vision can be restored, but the high rejection rate makes it an unreliable treatment
Solution Approach 1:
The patent converts the harmful effect of GAG accumulation causing corneal clouding into a beneficial outcome by delivering ARSB enzyme that specifically degrades these GAGs. The treatment targets the root cause (GAG accumulation in corneal stromal cells) rather than replacing the cornea, thereby avoiding rejection issues while restoring vision.
Solution Approach 2:
The AAV vector serves as an intermediary that delivers therapeutic gene material without triggering the immune rejection response that occurs with corneal transplantation. The viral vector mediates enzyme delivery in a way that is more compatible with the host immune system, reducing rejection risks.
3Adaptability or versatility
If systemic enzyme replacement therapy is administered to treat MPS VI, then multisystem organ damage is addressed, but the eye remains a privileged compartment that does not receive therapeutic enzyme
Solution Approach 1:
The patent applies segmentation by dividing the treatment approach into two complementary parts: systemic ERT/HSCT for multisystem organ involvement and localized AAV vector injection for ocular symptoms. This segmented strategy allows each treatment modality to optimize its effectiveness for its specific target compartment.
Solution Approach 2:
The AAV vector acts as a specialized intermediary that bridges the gap between systemic treatment and ocular delivery. While systemic ERT provides broad coverage, the AAV vector specifically mediates enzyme delivery to the cornea, overcoming the blood-eye barrier that prevents effective systemic treatment of the eye.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AAV vector-mediated delivery of ARSB effectively reduces corneal clouding and improves ocular health in MPS VI patients by expressing the enzyme throughout the cornea, slowing disease progression and delaying onset of ocular symptoms.
Implementation Method 1
arylsulfatase B (ARSB), a ubiquitous intracellular, cellular surface, and secreted enzyme that catabolizes large sugar molecules known as glycosaminoglycans (GAGs)
Data Source
AI summary
This invention relates to vectors for delivery of ary lsulfatase B to the eye (e.g., cornea) of a subject and methods of using the same for treatment and pre-vention of corneal clouding and blindness in a subject due to mucopolysaccharidosis VI (MPS-VI) and other MPS VI-associated manifestations in the eye.